Business Context and Reporting Period
Company: Curis, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Business Overview: Curis is a therapeutic drug development company focused on regulatory signaling pathways (specifically Bone Morphogenic Protein and Hedgehog families) to treat kidney disease, neurological disorders, cancer, and hair regrowth. The company operates primarily through strategic alliances and licensing agreements rather than internal commercialization.
Key Financial Metrics
| Metric (in thousands) | 2002 | 2001 |
|---|---|---|
| Total Revenues | $18,391 | $1,087 |
| Net Loss | $(82,315) | $(81,864) |
| Net Loss Applicable to Common Stockholders | $(83,038) | $(82,190) |
| Net Loss Per Share (Basic & Diluted) | $(2.57) | $(2.58) |
| Cash, Cash Equivalents & Marketable Securities | $40,976 | $52,107 |
| Working Capital | $35,100 | $42,848 |
| Total Debt & Lease Obligations (Long-term) | $3,424 | $4,951 |
| Convertible Notes Payable | $6,885 | $2,507 |
Note: Revenue in 2002 was heavily influenced by one-time license fees and the monetization of future royalty streams.
Material Changes vs. Prior Period
- Revenue Surge: Total revenues increased 1,592% to $18.4 million, driven primarily by a $14 million cash payment from Stryker Corporation to terminate future royalty obligations and a $3.5 million upfront fee from Ortho Biotech.
- Restructuring & Realignment: In February 2002, the company realigned R&D, terminating cell therapy programs, reducing the workforce by 46 employees, and incurring $3.5 million in cash restructuring expenses and $5.3 million in non-cash asset impairments. A further reduction of 14 employees occurred in December 2002.
- Goodwill Impairment: A non-cash charge of $64.1 million was recorded for goodwill impairment due to a decline in market capitalization, following the adoption of SFAS No. 142.
- Operating Expenses: Research and development expenses decreased 52% to $14.1 million due to the realignment and reduced workforce. General and administrative expenses decreased 22% to $8.2 million.
- Stock-Based Compensation: Decreased 79% to $2.2 million, largely due to the amortization of merger-related deferred compensation ending and the forfeiture of options by terminated employees.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing capital resources ($41 million in cash and equivalents) are sufficient to fund operations into the first quarter of 2005. Future funding beyond this period depends on successful collaborations or additional equity/debt financing.
- Strategic Focus: The company is shifting focus to maximizing returns on remaining assets via partnerships. Key alliances include Ortho Biotech (kidney disease), Elan (neurological disorders), Amylin (obesity), and ES Cell (diabetes). The company is seeking partners for its Hedgehog Antibody Cancer Program and Basal Cell Carcinoma Program.
- Listing Risk: The company received notice from NASDAQ that its stock price had closed below the $1.00 minimum bid price requirement for 30 consecutive days. It has until May 27, 2003, to regain compliance to avoid delisting.
- Key Risks:
- Dependence on strategic partners for development and commercialization.
- No commercial products currently on the market; all candidates are in preclinical or early clinical stages.
- Need for additional financing to sustain operations beyond 2005.
- Uncertainty regarding patent protection and potential litigation.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "first quarter of 2005" liquidity projection given the high cash burn rate and lack of recurring product revenue.
- Revenue Quality: Confirm that the $18.4 million revenue figure is non-recurring (license fees/asset sales) and does not reflect sustainable operating income.
- Partnership Milestones: Monitor the status of the Ortho Biotech and Elan joint ventures, as future revenue is contingent on achieving clinical and regulatory milestones.
- NASDAQ Compliance: Track the stock price to ensure it meets the $1.00 minimum bid requirement to avoid delisting.
- Goodwill Valuation: Review the assumptions used in the goodwill impairment test, as future impairments could significantly impact net loss if market capitalization declines further.